Key result
Atorvastatin calcium combined with clopidogrel significantly lowered blood lipids in TIA patients, but platelet-related indices did not exhibit significant differences between groups (P>0.05).
Why the study?
To explore the clinical effect of atorvastatin calcium combined with clopidogrel on blood lipids and platelets in patients with transient ischemic attacks.
Does atorvastatin calcium combined with clopidogrel improve blood lipids and platelet parameters in patients with transient ischemic attacks?
Does atorvastatin calcium combined with clopidogrel improve blood lipids and platelet parameters in patients with transient ischemic attacks?
p-value: p=> 0.05
In patients with TIAs, atorvastatin combined with clopidogrel significantly lowers lipid levels but does not significantly alter platelet parameters compared to control.
May support lipid management in TIA; leaves open effects on platelets or outcomes.
OBJECTIVE: To explore the clinical effect of atorvastatin calcium combined with clopidogrel in the treatment of patients with transient ischemic attacks (TIAs) and its effect on blood lipids and platelets. METHODS: Low-density lipoprotein cholesterol (LDL-C)], platelet-related parameters [prothrombin time (PT), activated partial thromboplastin time (APTT), platelet count (PLT)], incidence of cerebral infarction, and adverse reactions. CONCLUSION: Atorvastatin calcium combined with clopidogrel demonstrates a positive impact on individuals with TIAs by significantly lowering levels of LDL, total cholesterol, and triglycerides. However, it is noteworthy that platelet-related indices did not exhibit significant differences between the experimental and control groups. While the observed improvements in blood lipids are attributed to the effects of atorvastatin, the combination with clopidogrel did not show a substantial influence on platelet-related parameters. Thus, the overall therapeutic impact, particularly on platelet-related indices, may require further investigation and clarification. Despite these nuances, our findings suggest potential benefits in reducing the risk of adverse reactions and cerebral infarction, supporting the consideration of this approach for wider clinical use.
No takes yet. Share an insight, caveat, or question.
Zhong et al. (2024) studied Transient ischemic attacks (TIAs). Atorvastatin calcium combined with clopidogrel vs. Control group was evaluated on Blood lipids and platelet-related parameters (p=> 0.05). Atorvastatin calcium combined with clopidogrel significantly lowered blood lipids in TIA patients, but platelet-related indices did not exhibit significant differences between groups (P>0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: